11.38
+1.16%
Close of 9 Nov 2026, in EUR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Grifols
Its shares trade on BME under the ticker GRF.MC. It has been listed since 17 May 2006. In the fiscal year to 31 December 2025, it reported revenue of €7.52bn and net income of €401.9m. At that date it held total assets of €19.71bn and shareholders' equity of €5.27bn.
Grifols SA engages in the production of plasma derivatives. The company is headquartered in Barcelona, Barcelona. The company went IPO on 2006-05-17. The company organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Bio Supplies provides, mostly, biological products for non-therapeutic use. Others provides manufacturing services to third party companies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 17 May 2006
- Employees
- 23,668
Leadership
Pay as last reported
- Ms. Anne-Catherine BernerIndependent Chairman of the Board€75,000
- Mr. Jose Ignacio AbiaChief Executive Officer, Executive Director, since 2024€4.2m
- Mr. Raimon Grifols RouraVice Chairman of the Board, Proprietary Director, since 2001€4.0m
- Mr. Rahul SrinivasanChief Financial Officer
- Mr. Jordi Balsells VallsPresident - Plasma Procurement
- Mr. Antonio Martinez MartinezPresident - Diagnostic, since 2022
- Mr. Roland WandelerPresident - Biopharma
- Mr. Camille AlpiChief Human Resources & Talent Officer
- Mr. Lluis Pons GomezSenior Vice President - Strategy
- Mr. Jaime GonzalezChief Digital Information Officer
- Mr. Joerg SchuettrumpfChief Scientific Innovation Officer
- Mr. Enrique De La TorreChief Compliance Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 73
- Environment
- 99
- Social
- 99
- Governance
- 20
- Direct emissions (scope 1)
- 106,289 t
- Energy emissions (scope 2)
- 84,343 t
- Value chain emissions (scope 3)
- 1,051,606 t
- Women in the workforce
- 57%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Grifols SA is a global leader in the healthcare sector, specializing in the production of plasma derivatives and laboratory testing. The company's major strengths include:
Weaknesses
- Despite its market leadership, Grifols SA faces certain weaknesses that could pose challenges:
Opportunities
- Grifols SA can leverage the following opportunities to enhance its growth prospects:
Threats
- Grifols SA needs to address the following threats in order to mitigate potential risks:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.